Company Profile
Inhibrx Stock Price, News & Analysis
- Ticker:
- INBX
- Exchange:
- NASDAQ
- Sector:
- Biopharmaceuticals
- Location:
- United States
Stock performance
91.22 USD (-2.13%)
Close
Last updated: July 15, 2026 at 00:00
1.36B USD
Market cap
Why the stock is moving
INBX is trading like a clinical-stage oncology name where the main driver is whether the next update strengthens confidence in the pipeline. The stock usually reacts to readouts, safety, financing, and partnership signals more than to broad sector moves.
Company overview
Business overview
Inhibrx is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Inhibrx is followed within the biotech universe for its exposure to catalyst-driven execution.
Business Model Characteristics
Inhibrx follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.
Position Within the Biotechnology Landscape
Compared with more mature healthcare peers, Inhibrx sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.
Future catalysts
The next three months should center on clinical updates, development milestones, and any commentary that clarifies the path for ozekibart or the broader biologics platform.
Investors will also watch financing flexibility and strategic alternatives because clinical-stage oncology names tend to reprice quickly when capital structure or partner interest changes.
Conference posters, investigator updates, and regulatory feedback can all matter if they change the market's confidence in activity or differentiation.
For a company like Inhibrx, one clear efficacy or safety signal can move the investment case more than several smaller follow-on updates.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
- 02
- 03
Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results
ALNY · Source: Alnylam Pharmaceuticals, Inc.
- 04
GSK completes acquisition of Nuvalent, Inc.
GSK · Source: GSK plc
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Inhibrx (INBX)?
Inhibrx (INBX) most recently closed at 91.22 USD, a -2.13% move versus the previous session.
What is the market cap of Inhibrx (INBX)?
Inhibrx currently has a market capitalization of 1.36B USD on BioPharmSignal.
What does Inhibrx do?
Inhibrx is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
On which exchange is INBX stock listed?
Inhibrx (INBX) is associated with NASDAQ, United States, Biopharmaceuticals.
What is Inhibrx?
For a company like Inhibrx, one clear efficacy or safety signal can move the investment case more than several smaller follow-on updates.
Which conditions is Inhibrx targeting with Inhibrx?
Inhibrx is associated with oncology based on its company overview and current catalyst commentary.
How does Inhibrx describe recent progress with Inhibrx?
For a company like Inhibrx, one clear efficacy or safety signal can move the investment case more than several smaller follow-on updates.
What is Investors?
Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.